Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 19/20 | 0.67 |
| ▸ | BCL2L1 | Q07817 | 15/20 | 0.67 |
| ▸ | BAK1 | Q16611 | 4/20 | 0.67 |
| ▸ | MDM4 | O15151 | 1/20 | 0.61 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | BID | P55957 | 1/20 | 0.61 |
| ▸ | BAX | Q07812 | 1/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.61 |
| ▸ | ASPH | Q12797 | 1/20 | 0.61 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.61 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.61 |
| ▸ | BAD | Q92934 | 1/20 | 0.61 |
| ▸ | BBC3 | Q9BXH1 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994558 | 0.92 | BCL2 (0.71) | BCL2BCL2L1BAK1 | |
| SCHEMBL2388437 | 0.89 | BCL2 (0.71) | BCL2BCL2L1BAK1MDM4BCL2L11 | |
| SCHEMBL2990459 | 0.88 | BCL2 (0.79) | BCL2BCL2L1BAK1 | |
| SCHEMBL2985732 | 0.88 | BCL2 (0.60) | BCL2 | |
| SCHEMBL1743437 | 0.87 | BCL2 (0.71) | BCL2BCL2L1BAK1 | |
| SCHEMBL2986855 | 0.87 | BCL2 (0.66) | BCL2 | |
| SCHEMBL2990010 | 0.87 | BCL2 (0.59) | BCL2 | |
| SCHEMBL1743536 | 0.86 | BCL2 (0.59) | BCL2 | |
| SCHEMBL2996288 | 0.86 | BCL2 (0.58) | BCL2BCL2L1 | |
| SCHEMBL1743317 | 0.86 | BCL2 (0.73) | BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2511264-B1 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC (US) | 2015-03-11 | — | — | EP | claimed |
| US-20100184750-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | US | claimed |
| EP-2511264-B1 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8426422-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2511264-A1 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Abbott Laboratories (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2387560-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8042193-B1 | Systems and methods for controlling data access by use of a universal anonymous identifier | Albright Associates (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100184750-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010083441-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2008064116-A2 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184750-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885BCL2L1 4/4885BAK1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.